Guidelines for Prevention of Group B Streptococcal (GBS) Infection by Chemoprophylaxis

BACKGROUND For two decades streptococci classified serologically as Lancefield group B Streptococcus agalactiae (GBS) have been a leading cause of perinatal infections. In neonates and young infants these infections include congenital pneumonia, sepsis, or meningitis; in pregnant women they include...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatrics (Evanston) 1992-11, Vol.90 (5), p.775-778
1. Verfasser: Committee on Infectious Diseases and Committee on Fetus and Newborn
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 778
container_issue 5
container_start_page 775
container_title Pediatrics (Evanston)
container_volume 90
creator Committee on Infectious Diseases and Committee on Fetus and Newborn
description BACKGROUND For two decades streptococci classified serologically as Lancefield group B Streptococcus agalactiae (GBS) have been a leading cause of perinatal infections. In neonates and young infants these infections include congenital pneumonia, sepsis, or meningitis; in pregnant women they include urinary tract infection, chorioamnionitis, early postpartum endometritis, postcesarean section febrile morbidity, and—less frequently—pelvic thrombophlebitis or endocarditis. Although the incidence varies somewhat by geographic region, 12 000 infants and 50 000 pregnant women in the United States are estimated to develop GBS-associated morbidity or mortality annually.1 Overall mortality for early-onset (less than 7 days of age) and late-onset (7 days to 3 months of age) infant disease is approximately 15% and 10%, respectively.2-4 Gestational age significantly correlates with mortality among early-onset cases and is approximately 25% to 30% in preterm infants and 2% to 8% in term infants. Thus, every year approximately 1 600 infants die and an equal number have permanent neurologic sequelae following meningitis.1 This substantial GBS-associated perinatal mortality and morbidity make prevention strategies imperative. Among proposed strategies, including chemoprophylaxis and immunoprophylaxis, only intrapartum maternal chemoprophylaxis has been evaluated for safety and efficacy. EPIDEMIOLOGY GBS are frequently harbored in the genitourinary and lower gastrointestinal tracts of adults. When sensitive culture methods are used for their detection (ie, antibiotic-containing or selective broth media) and both lower vaginal and anorectal sites are sampled, GBS are found in 15% to 40% of pregnant women.5-8 Direct plating of swabs from body surfaces onto solid media or sampling of the cervix as a single genital tract site fails to identify as many as 50% of women who are culture-positive for GBS.4
doi_str_mv 10.1542/peds.90.5.775
format Article
fullrecord <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_incontextcollege_GICCO_A12920252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A12920252</galeid><sourcerecordid>A12920252</sourcerecordid><originalsourceid>FETCH-LOGICAL-c338t-54655a870d555d57ee119d1d59308443af4b8674f3071208d93a323b5432aff93</originalsourceid><addsrcrecordid>eNotkM9PwjAYhhujiYgevfeoiZtff3x0OwLRSUKCCeq1KVsLM2Nd2mHgvxfE03t58j7JQ8g9g5Sh5M-drWKaQ4qpUnhBBgzyLJFc4SUZAAiWSAC8JjcxfgOARMUH5KvY1ZVt6tZG6nyg78H-2LavfUu9o0Xwu45O6LIPtut96cvSNPShmCwf6ax1tvwDVwc63dit74LvNofG7Ot4S66caaK9-98h-Xx9-Zi-JfNFMZuO50kpRNYnKEeIJlNQIWKFylrG8opVmAvIpBTGyVU2UtIJUIxDVuXCCC5WKAU3zuViSJ7Ov2vTWF23pW97u-9L3zR2bfXRNV3oMeM5B478iCdnvAw-xmCd7kK9NeGgGehTQ31qqHPQqI8NxS9cQmOd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Guidelines for Prevention of Group B Streptococcal (GBS) Infection by Chemoprophylaxis</title><source>EZB Electronic Journals Library</source><creator>Committee on Infectious Diseases and Committee on Fetus and Newborn</creator><creatorcontrib>Committee on Infectious Diseases and Committee on Fetus and Newborn</creatorcontrib><description>BACKGROUND For two decades streptococci classified serologically as Lancefield group B Streptococcus agalactiae (GBS) have been a leading cause of perinatal infections. In neonates and young infants these infections include congenital pneumonia, sepsis, or meningitis; in pregnant women they include urinary tract infection, chorioamnionitis, early postpartum endometritis, postcesarean section febrile morbidity, and—less frequently—pelvic thrombophlebitis or endocarditis. Although the incidence varies somewhat by geographic region, 12 000 infants and 50 000 pregnant women in the United States are estimated to develop GBS-associated morbidity or mortality annually.1 Overall mortality for early-onset (less than 7 days of age) and late-onset (7 days to 3 months of age) infant disease is approximately 15% and 10%, respectively.2-4 Gestational age significantly correlates with mortality among early-onset cases and is approximately 25% to 30% in preterm infants and 2% to 8% in term infants. Thus, every year approximately 1 600 infants die and an equal number have permanent neurologic sequelae following meningitis.1 This substantial GBS-associated perinatal mortality and morbidity make prevention strategies imperative. Among proposed strategies, including chemoprophylaxis and immunoprophylaxis, only intrapartum maternal chemoprophylaxis has been evaluated for safety and efficacy. EPIDEMIOLOGY GBS are frequently harbored in the genitourinary and lower gastrointestinal tracts of adults. When sensitive culture methods are used for their detection (ie, antibiotic-containing or selective broth media) and both lower vaginal and anorectal sites are sampled, GBS are found in 15% to 40% of pregnant women.5-8 Direct plating of swabs from body surfaces onto solid media or sampling of the cervix as a single genital tract site fails to identify as many as 50% of women who are culture-positive for GBS.4</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.90.5.775</identifier><language>eng</language><publisher>American Academy of Pediatrics</publisher><subject>Prevention ; Streptococcal infections ; Streptococcus agalactiae</subject><ispartof>Pediatrics (Evanston), 1992-11, Vol.90 (5), p.775-778</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c338t-54655a870d555d57ee119d1d59308443af4b8674f3071208d93a323b5432aff93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Committee on Infectious Diseases and Committee on Fetus and Newborn</creatorcontrib><title>Guidelines for Prevention of Group B Streptococcal (GBS) Infection by Chemoprophylaxis</title><title>Pediatrics (Evanston)</title><addtitle>Pediatrics</addtitle><description>BACKGROUND For two decades streptococci classified serologically as Lancefield group B Streptococcus agalactiae (GBS) have been a leading cause of perinatal infections. In neonates and young infants these infections include congenital pneumonia, sepsis, or meningitis; in pregnant women they include urinary tract infection, chorioamnionitis, early postpartum endometritis, postcesarean section febrile morbidity, and—less frequently—pelvic thrombophlebitis or endocarditis. Although the incidence varies somewhat by geographic region, 12 000 infants and 50 000 pregnant women in the United States are estimated to develop GBS-associated morbidity or mortality annually.1 Overall mortality for early-onset (less than 7 days of age) and late-onset (7 days to 3 months of age) infant disease is approximately 15% and 10%, respectively.2-4 Gestational age significantly correlates with mortality among early-onset cases and is approximately 25% to 30% in preterm infants and 2% to 8% in term infants. Thus, every year approximately 1 600 infants die and an equal number have permanent neurologic sequelae following meningitis.1 This substantial GBS-associated perinatal mortality and morbidity make prevention strategies imperative. Among proposed strategies, including chemoprophylaxis and immunoprophylaxis, only intrapartum maternal chemoprophylaxis has been evaluated for safety and efficacy. EPIDEMIOLOGY GBS are frequently harbored in the genitourinary and lower gastrointestinal tracts of adults. When sensitive culture methods are used for their detection (ie, antibiotic-containing or selective broth media) and both lower vaginal and anorectal sites are sampled, GBS are found in 15% to 40% of pregnant women.5-8 Direct plating of swabs from body surfaces onto solid media or sampling of the cervix as a single genital tract site fails to identify as many as 50% of women who are culture-positive for GBS.4</description><subject>Prevention</subject><subject>Streptococcal infections</subject><subject>Streptococcus agalactiae</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNotkM9PwjAYhhujiYgevfeoiZtff3x0OwLRSUKCCeq1KVsLM2Nd2mHgvxfE03t58j7JQ8g9g5Sh5M-drWKaQ4qpUnhBBgzyLJFc4SUZAAiWSAC8JjcxfgOARMUH5KvY1ZVt6tZG6nyg78H-2LavfUu9o0Xwu45O6LIPtut96cvSNPShmCwf6ax1tvwDVwc63dit74LvNofG7Ot4S66caaK9-98h-Xx9-Zi-JfNFMZuO50kpRNYnKEeIJlNQIWKFylrG8opVmAvIpBTGyVU2UtIJUIxDVuXCCC5WKAU3zuViSJ7Ov2vTWF23pW97u-9L3zR2bfXRNV3oMeM5B478iCdnvAw-xmCd7kK9NeGgGehTQ31qqHPQqI8NxS9cQmOd</recordid><startdate>19921101</startdate><enddate>19921101</enddate><creator>Committee on Infectious Diseases and Committee on Fetus and Newborn</creator><general>American Academy of Pediatrics</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19921101</creationdate><title>Guidelines for Prevention of Group B Streptococcal (GBS) Infection by Chemoprophylaxis</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c338t-54655a870d555d57ee119d1d59308443af4b8674f3071208d93a323b5432aff93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Prevention</topic><topic>Streptococcal infections</topic><topic>Streptococcus agalactiae</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Committee on Infectious Diseases and Committee on Fetus and Newborn</creatorcontrib><collection>CrossRef</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><aucorp>Committee on Infectious Diseases and Committee on Fetus and Newborn</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Guidelines for Prevention of Group B Streptococcal (GBS) Infection by Chemoprophylaxis</atitle><jtitle>Pediatrics (Evanston)</jtitle><addtitle>Pediatrics</addtitle><date>1992-11-01</date><risdate>1992</risdate><volume>90</volume><issue>5</issue><spage>775</spage><epage>778</epage><pages>775-778</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><abstract>BACKGROUND For two decades streptococci classified serologically as Lancefield group B Streptococcus agalactiae (GBS) have been a leading cause of perinatal infections. In neonates and young infants these infections include congenital pneumonia, sepsis, or meningitis; in pregnant women they include urinary tract infection, chorioamnionitis, early postpartum endometritis, postcesarean section febrile morbidity, and—less frequently—pelvic thrombophlebitis or endocarditis. Although the incidence varies somewhat by geographic region, 12 000 infants and 50 000 pregnant women in the United States are estimated to develop GBS-associated morbidity or mortality annually.1 Overall mortality for early-onset (less than 7 days of age) and late-onset (7 days to 3 months of age) infant disease is approximately 15% and 10%, respectively.2-4 Gestational age significantly correlates with mortality among early-onset cases and is approximately 25% to 30% in preterm infants and 2% to 8% in term infants. Thus, every year approximately 1 600 infants die and an equal number have permanent neurologic sequelae following meningitis.1 This substantial GBS-associated perinatal mortality and morbidity make prevention strategies imperative. Among proposed strategies, including chemoprophylaxis and immunoprophylaxis, only intrapartum maternal chemoprophylaxis has been evaluated for safety and efficacy. EPIDEMIOLOGY GBS are frequently harbored in the genitourinary and lower gastrointestinal tracts of adults. When sensitive culture methods are used for their detection (ie, antibiotic-containing or selective broth media) and both lower vaginal and anorectal sites are sampled, GBS are found in 15% to 40% of pregnant women.5-8 Direct plating of swabs from body surfaces onto solid media or sampling of the cervix as a single genital tract site fails to identify as many as 50% of women who are culture-positive for GBS.4</abstract><pub>American Academy of Pediatrics</pub><doi>10.1542/peds.90.5.775</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0031-4005
ispartof Pediatrics (Evanston), 1992-11, Vol.90 (5), p.775-778
issn 0031-4005
1098-4275
language eng
recordid cdi_gale_incontextcollege_GICCO_A12920252
source EZB Electronic Journals Library
subjects Prevention
Streptococcal infections
Streptococcus agalactiae
title Guidelines for Prevention of Group B Streptococcal (GBS) Infection by Chemoprophylaxis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A01%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Guidelines%20for%20Prevention%20of%20Group%20B%20Streptococcal%20(GBS)%20Infection%20by%20Chemoprophylaxis&rft.jtitle=Pediatrics%20(Evanston)&rft.aucorp=Committee%20on%20Infectious%20Diseases%20and%20Committee%20on%20Fetus%20and%20Newborn&rft.date=1992-11-01&rft.volume=90&rft.issue=5&rft.spage=775&rft.epage=778&rft.pages=775-778&rft.issn=0031-4005&rft.eissn=1098-4275&rft_id=info:doi/10.1542/peds.90.5.775&rft_dat=%3Cgale_cross%3EA12920252%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A12920252&rfr_iscdi=true